StreetAlpha.app
Home › Stocks › GERN

Geron Corp (GERN)

Healthcare
$0.87
▼ −4.63%
LAST CLOSE · NOV 20

Geron is a biopharmaceutical company that sells RYTELO, a treatment for certain blood cancers. It last closed at $0.87 on Nov 20, down 4.63% on the day. The next earnings report for GERN is expected around Wed, Feb 24, 2027. For the quarter ended Sep 2026, GERN reported EPS of $0.00 on revenue of $60.2M, with revenue up 27.4% from a year ago. Over its last 8 reports the stock moved an average of 11.4% the session after earnings. Over the last 12 months GERN insiders bought $62K of stock on the open market and sold $19K, according to SEC Form 4 filings.

AI Auto Pilots
Is GERN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold GERN.

Key Stats

Last 12 months
Results
Net income
−$47.8M
EPS (diluted)
−$0.08
Valuation
Market cap
$560.9M
644.2M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$69.2M
At Sep 30
Debt
$120.4M
At Sep 30
Shareholder equity
$226.7M
Shares outstanding
644.2M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.4M$1.4MFY2021FY2022: $596K$596KFY2022FY2023: $237K$237KFY2023

From GERN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Feb 24
Estimated date · Time not announced
Reported EPS
$0.00
Quarter ended Sep 2026
Year ago EPS
-$0.03
Same quarter last year
Revenue
$60.2M
+27.4% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.04Dec '24Mar 2025: -$0.03Mar '25Jun 2025: -$0.02Jun '25Sep 2025: -$0.03Sep '25Dec 2025: -$0.05Dec '25Mar 2026: -$0.01Mar '26Jun 2026: -$0.02Jun '26Sep 2026: $0.00Sep '26Latest $0.00
Revenue by quarter
Mar 2025: $39.6MMar '25Jun 2025: $49.0MJun '25Sep 2025: $47.2MSep '25Mar 2026: $51.8MMar '26Jun 2026: $57.5MJun '26Sep 2026: $60.2MSep '26Latest $60.2M
How GERN moved after its last 8 reports
Average move the session after a report ±11.4%
Nov 4, 2026Time not announced+16.1%
Aug 6, 2026Time not announced−3.7%
Feb 25, 2026Time not announced−11.8%
Nov 5, 2025Time not announced−5.2%
Aug 6, 2025Time not announced+15.8%
May 7, 2025Time not announced−0.8%
Feb 26, 2025Time not announced−32.1%
Jan 13, 2025Time not announced−6.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on GERNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on GERN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on GERN

Technical Analysis

GERN · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 13% below its 20 day and 30% below its 50 day average. It is 60% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 35), near oversold. The nearest support is the Pivot S1 at $0.85, and the nearest resistance the Pivot at $0.89.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 8.4%/day
Key levels
$2.0152 week high+131.0%
$1.39200 day average+59.8%
$1.30100 day average+49.4%
$1.1350 day average+29.9%
$1.02Swing high (Nov 17)+17.2%
$0.9820 day average+12.6%
$0.91Pivot R1+4.6%
$0.89Pivot+2.3%
$0.87Last close
$0.85Pivot S1−2.3%
$0.8452 week low−3.4%
$0.84Swing low (Oct 28)−3.4%
Indicators
RSI (14)35.41Weak, oversold below 30Neutral
MACD-0.06Below its signal lineBearish
Stochastic24.9Middle of its rangeNeutral
ADX (14)34.4Trending down
Williams %R-96.0Oversold below −80, overbought above −20Oversold
CCI (20)-146.4Oversold below −100, overbought above 100Oversold
Rate of change−12.0%Change over 10 sessionsBearish
ATR (14)$0.07Typical daily range, 8.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for GERN

What happened before

See how GERN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow GERN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How GERN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for GERNHow many large options trades hit GERN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

GERN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲112 buying vs 83 selling
  • ▼Held by funds -5.0 pts
  • ●Funds holding +0
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2612610.0%
In funds' top 1010–
Held by funds70.9%75.9%−5.0 pts
New / increased26 / 8634 / 95−13.2%
Reduced / sold out59 / 2461 / 30−8.8%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GERN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

GERN Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$62K2 buys · 2 insiders
Sold$19K1 sale · 1 insider
Cluster buy: 2 insiders bought $62K between Nov 13 and Nov 16.
2026-02 sold $19K2026-11 bought $62KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Timothy WilliamsEVP and Chief Legal OfficerBuy12,000$0.94$11K
Nov 13Harout SemerjianPresident & CEOBuy53,500$0.95$51K
Feb 18Michelle RobertsonEvp, CFOSale9,855$1.94$19K
May 9, 2025V Bryan LawlisDirectorBuy13,300$1.18$16K
Feb 27, 2025James ZieglerEVP, Chief Commercial OfficerBuy100,000$1.60$160K
Feb 27, 2025John A ScarlettChairman, President and CEOBuy12,500$1.77$22K
Every insider buy and sale for GERN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See GERN insider trades →

From SEC Form 4 filings by GERN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GERN is in one of them and how their past GERN trades turned out.

GERN in the AI portfolios
Loading…

GERN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GERN in an article yet. Here's the latest on the wider market.

GERN in the news

About Geron

Geron is a biopharmaceutical company based in Foster City, California, that develops treatments for blood cancers. Its main product is RYTELO, a telomerase inhibitor approved in the United States for adults with myelodysplastic syndrome who need frequent red blood cell transfusions. The company sells RYTELO to patients and health care providers in the U.S. and plans to make it available in select European Union markets through outside partners. It is also testing the drug in myelofibrosis, another blood cancer.

Headquarters
Foster City, CA
Founded
1990